UBS Group Initiates Coverage on Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Key Points

• UBS initiated coverage with a Buy rating and a $109 price target, implying approximately 86.5% upside from Arrowhead Pharmaceuticals’ reported share price of $58.44.
• Analyst sentiment is broadly positive: 11 analysts rate the stock Buy, three Hold, and one Sell, resulting in a “Moderate Buy” consensus and an average target price of $99.07.
• Arrowhead reported encouraging interim ARO-MAPT data showing up to a 73% reduction in tau, supporting its TRiM platform’s ability to cross the blood-brain barrier. However, the early-stage results demonstrate biomarker reduction—not yet improved cognition or slower Alzheimer’s progression—and the company recently missed quarterly EPS estimates despite strong revenue growth.

Stock analysts at UBS Group assumed coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) in a research note issued on Thursday. The brokerage set a "buy" rating and a $109.00 price target on the biotechnology company's stock. UBS Group's target price would indicate a potential upside of 86.53% from the company's current price.

Several other research firms have also issued reports on ARWR. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 17th. HC Wainwright reissued a "buy" rating and set a $120.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday. Morgan Stanley increased their price target on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an "overweight" rating in a report on Thursday, July 23rd. Citigroup assumed coverage on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, September 8th. They set a "buy" rating and a $108.00 price objective for the company. Finally, Leerink Partners boosted their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a "market perform" rating in a research report on Wednesday, June 17th. Eleven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $99.07.

Arrowhead Pharmaceuticals Price Performance

Shares of Arrowhead Pharmaceuticals stock traded up $0.07 during trading hours on Thursday, reaching $58.44. The company's stock had a trading volume of 855,724 shares, compared to its average volume of 2,286,365. The firm has a 50 day moving average price of $76.71 and a 200-day moving average price of $75.99. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. The stock has a market cap of $8.23 billion, a P/E ratio of -26.01 and a beta of 1.29. Arrowhead Pharmaceuticals has a one year low of $36.57 and a one year high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The business had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. During the same period in the previous year, the business posted ($1.26) EPS. The firm's revenue was up 171.0% on a year-over-year basis. On average, analysts predict that Arrowhead Pharmaceuticals will post -3.62 EPS for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Michael Perry sold 11,600 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the transaction, the director directly owned 111,459 shares in the company, valued at $9,730,370.70. This represents a 9.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Adeoye Olukotun sold 2,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the transaction, the director directly owned 31,600 shares in the company, valued at approximately $2,747,936. The trade was a 5.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Assenagon Asset Management S.A. boosted its stake in Arrowhead Pharmaceuticals by 243.8% in the second quarter. Assenagon Asset Management S.A. now owns 201,927 shares of the biotechnology company's stock valued at $16,459,000 after acquiring an additional 143,192 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the second quarter worth $20,859,000. Siren L.L.C. increased its position in shares of Arrowhead Pharmaceuticals by 7.7% during the first quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company's stock worth $101,290,000 after purchasing an additional 115,000 shares in the last quarter. Corient Private Wealth LP purchased a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $1,313,000. Finally, Empowered Funds LLC boosted its position in shares of Arrowhead Pharmaceuticals by 661.6% in the 1st quarter. Empowered Funds LLC now owns 137,220 shares of the biotechnology company's stock worth $8,604,000 after purchasing an additional 119,202 shares in the last quarter. Institutional investors own 62.61% of the company's stock.

Key Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Positive ARO-MAPT results: Interim Phase 1/2a data showed up to a 73% reduction in tau, a protein associated with Alzheimer’s disease, with reductions described as deep and durable in healthy volunteers. The company said the results provide the first clinical validation of its TRiM platform’s ability to deliver siRNA across the blood-brain barrier and reduce a target gene in the brain. Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data
• Positive Sentiment: Alzheimer’s program strengthens the pipeline: The reported ability to cross the blood-brain barrier could support ARO-MAPT and other programs using Arrowhead’s TRiM CNS delivery platform. Coverage highlighted the potential significance of the early-stage data, although the study remains investigational and was conducted in healthy volunteers. Arrowhead Reports Positive Phase 1/2a Data for Alzheimer’s Candidate ARO-MAPT
• Positive Sentiment: Analysts reaffirm bullish views: Chardan Capital reiterated its “buy” rating and set a $115 price target, while HC Wainwright also reaffirmed “buy” with a $120 target. Both targets imply substantial upside from recent trading levels, providing additional support for investor sentiment.
• Neutral Sentiment: Important clinical caveat: The ARO-MAPT findings are interim Phase 1/2a results and primarily demonstrate biomarker reduction and delivery, not yet proof that the therapy improves cognition or slows Alzheimer’s disease. Further clinical testing will be needed to establish efficacy and safety. Arrowhead Discusses ARO-MAPT Interim Results and TRiM CNS Delivery
• Neutral Sentiment: Some coverage noted differing analyst views on healthcare stocks, including Arrowhead, indicating that valuation and execution risks remain despite the favorable ARO-MAPT update.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.